Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Polychromic Reporter Mice Reveal Unappreciated Innate Lymphoid Cell Progenitor Heterogeneity and Elusive ILC3 Progenitors in Bone Marrow.

Walker JA, Clark PA, Crisp A, Barlow JL, Szeto A, Ferreira ACF, Rana BMJ, Jolin HE, Rodriguez-Rodriguez N, Sivasubramaniam M, Pannell R, Cruickshank J, Daly M, Haim-Vilmovsky L, Teichmann SA, McKenzie ANJ.

Immunity. 2019 May 20. pii: S1074-7613(19)30201-8. doi: 10.1016/j.immuni.2019.05.002. [Epub ahead of print]

PMID:
31128961
2.

A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: comment.

Gurewich V, Pannell R.

J Thromb Haemost. 2017 Oct;15(10):2080-2081. doi: 10.1111/jth.13797. Epub 2017 Sep 6. No abstract available.

PMID:
28799246
3.

Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Pannell R, Li S, Gurewich V.

J Thromb Thrombolysis. 2017 Aug;44(2):210-215. doi: 10.1007/s11239-017-1514-0.

PMID:
28600623
4.

25 hydroxy vitamin D is higher when a renal multivitamin is given with cholecalciferol at hemodialysis.

Subih HS, Behrens J, Burt B, Clement L, Pannell R, Macha L, Spallholz J, Boylan M.

Asia Pac J Clin Nutr. 2016 Dec;25(4):754-759. doi: 10.6133/apjcn.012016.08.

5.

Structure-function relationships in thrombin-activatable fibrinolysis inhibitor: comment.

Gurewich V, Pannell R.

J Thromb Haemost. 2016 Sep;14(9):1899-900. doi: 10.1111/jth.13396. Epub 2016 Aug 24. No abstract available.

6.

Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.

Pannell R, Li S, Gurewich V.

PLoS One. 2015 Mar 26;10(3):e0122018. doi: 10.1371/journal.pone.0122018. eCollection 2015.

7.

Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13.

Camelo A, Barlow JL, Drynan LF, Neill DR, Ballantyne SJ, Wong SH, Pannell R, Gao W, Wrigley K, Sprenkle J, McKenzie AN.

J Gastroenterol. 2012 Nov;47(11):1198-211. doi: 10.1007/s00535-012-0591-2. Epub 2012 Apr 27.

8.

Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia.

Hodson DJ, Janas ML, Galloway A, Bell SE, Andrews S, Li CM, Pannell R, Siebel CW, MacDonald HR, De Keersmaecker K, Ferrando AA, Grutz G, Turner M.

Nat Immunol. 2010 Aug;11(8):717-24. doi: 10.1038/ni.1901. Epub 2010 Jul 11. Erratum in: Nat Immunol. 2010 Oct;11(10):969.

9.

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity.

Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN.

Nature. 2010 Apr 29;464(7293):1367-70. doi: 10.1038/nature08900. Epub 2010 Mar 3.

10.

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, Jolin HE, Pannell R, Middleton AJ, Wong SH, Warren AJ, Wainscoat JS, Boultwood J, McKenzie AN.

Nat Med. 2010 Jan;16(1):59-66. doi: 10.1038/nm.2063. Epub 2009 Nov 22.

11.

Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.

Gurewich V, Pannell R.

Thromb Haemost. 2009 Aug;102(2):279-86. doi: 10.1160/TH08-09-0598.

PMID:
19652878
12.

Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias.

Lobato MN, Metzler M, Drynan L, Forster A, Pannell R, Rabbitts TH.

J Natl Cancer Inst Monogr. 2008;(39):58-63. doi: 10.1093/jncimonographs/lgn022.

PMID:
18648005
13.

The role of Slit-Robo signaling in the generation, migration and morphological differentiation of cortical interneurons.

Andrews W, Barber M, Hernadez-Miranda LR, Xian J, Rakic S, Sundaresan V, Rabbitts TH, Pannell R, Rabbitts P, Thompson H, Erskine L, Murakami F, Parnavelas JG.

Dev Biol. 2008 Jan 15;313(2):648-58. Epub 2007 Nov 13.

14.

Leukaemia lineage specification caused by cell-specific Mll-Enl translocations.

Cano F, Drynan LF, Pannell R, Rabbitts TH.

Oncogene. 2008 Mar 20;27(13):1945-50. Epub 2007 Oct 1.

PMID:
17906700
15.

Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.

Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H, Robert S, Lamy E, Plawinski L, Camoin-Jau L, Gurewich V, Angles-Cano E, Dignat-George F.

Blood. 2007 Oct 1;110(7):2432-9. Epub 2007 Jul 2.

16.
17.

Planning for pharmacy health information technology in critical access hospitals.

Hartzema AG, Winterstein AG, Johns TE, De Leon JM, Bailey W, McDonald K, Pannell R.

Am J Health Syst Pharm. 2007 Feb 1;64(3):315-21.

PMID:
17244881
18.

Chromosomal translocation engineering to recapitulate primary events of human cancer.

Forster A, Pannell R, Drynan L, Cano F, Chan N, Codrington R, Daser A, Lobato N, Metzler M, Nam CH, Rodriguez S, Tanaka T, Rabbitts T.

Cold Spring Harb Symp Quant Biol. 2005;70:275-82.

PMID:
16869763
19.

Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.

Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu JN, Badylak SF.

J Thromb Haemost. 2006 Jul;4(7):1559-65.

20.

Interrogation of genomes by molecular copy-number counting (MCC).

Daser A, Thangavelu M, Pannell R, Forster A, Sparrow L, Chung G, Dear PH, Rabbitts TH.

Nat Methods. 2006 Jun;3(6):447-53. Erratum in: Nat Methods. 2006 Jul;3(7):579.

PMID:
16721378
21.

A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology.

Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, Rabbitts TH.

Oncogene. 2006 May 25;25(22):3093-103.

PMID:
16607274
22.

Medication safety infrastructure in critical-access hospitals in Florida.

Winterstein AG, Hartzema AG, Johns TE, De Leon JM, McDonald K, Henshaw Z, Pannell R.

Am J Health Syst Pharm. 2006 Mar 1;63(5):442-50.

PMID:
16484518
23.

The incidence of molluscum contagiosum, scabies and lichen planus.

Pannell RS, Fleming DM, Cross KW.

Epidemiol Infect. 2005 Dec;133(6):985-91.

24.

Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.

Drynan LF, Pannell R, Forster A, Chan NM, Cano F, Daser A, Rabbitts TH.

EMBO J. 2005 Sep 7;24(17):3136-46. Epub 2005 Aug 11.

25.

The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells.

Codrington R, Pannell R, Forster A, Drynan LF, Daser A, Lobato N, Metzler M, Rabbitts TH.

PLoS Biol. 2005 Aug;3(8):e242. Epub 2005 Jun 28.

26.

Mortality in children from influenza and respiratory syncytial virus.

Fleming DM, Pannell RS, Cross KW.

J Epidemiol Community Health. 2005 Jul;59(7):586-90.

27.

Respiratory illness associated with influenza and respiratory syncytial virus infection.

Fleming DM, Pannell RS, Elliot AJ, Cross KW.

Arch Dis Child. 2005 Jul;90(7):741-6. Epub 2005 Apr 26.

28.

Influenza and its relationship to circulatory disorders.

Fleming DM, Cross KW, Pannell RS.

Epidemiol Infect. 2005 Apr;133(2):255-62.

29.

The invertor knock-in conditional chromosomal translocation mimic.

Forster A, Pannell R, Drynan LF, Codrington R, Daser A, Metzler M, Lobato MN, Rabbitts TH.

Nat Methods. 2005 Jan;2(1):27-30.

PMID:
15782166
30.

Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter.

Xian J, Aitchison A, Bobrow L, Corbett G, Pannell R, Rabbitts T, Rabbitts P.

Cancer Res. 2004 Sep 15;64(18):6432-7.

31.
32.

Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer.

Forster A, Pannell R, Drynan LF, McCormack M, Collins EC, Daser A, Rabbitts TH.

Cancer Cell. 2003 May;3(5):449-58.

33.
34.

Platelet associated u-PA up-regulates u-PA synthesis by endothelial cells.

Camoin-Jau L, Pannell R, Anfosso F, Bardin N, Sabatier F, Sampol J, Gurewich V, Dignat-George F.

Thromb Haemost. 2002 Sep;88(3):517-23.

PMID:
12353084
35.

Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia.

Collins EC, Appert A, Ariza-McNaughton L, Pannell R, Yamada Y, Rabbitts TH.

Mol Cell Biol. 2002 Oct;22(20):7313-24.

36.

The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.

Yamada Y, Pannell R, Forster A, Rabbitts TH.

Oncogene. 2002 Feb 21;21(9):1309-15.

37.

Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene.

Xian J, Clark KJ, Fordham R, Pannell R, Rabbitts TH, Rabbitts PH.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15062-6. Epub 2001 Dec 4.

38.

Gene targeting reveals a crucial role for MTG8 in the gut.

Calabi F, Pannell R, Pavloska G.

Mol Cell Biol. 2001 Aug;21(16):5658-66.

39.

Mouse models of human chromosomal translocations and approaches to cancer therapy.

Rabbitts TH, Appert A, Chung G, Collins EC, Drynan L, Forster A, Lobato MN, McCormack MP, Pannell R, Spandidos A, Stocks MR, Tanaka T, Tse E.

Blood Cells Mol Dis. 2001 Jan-Feb;27(1):249-59. Review.

PMID:
11358385
40.

Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development.

Collins EC, Pannell R, Simpson EM, Forster A, Rabbitts TH.

EMBO Rep. 2000 Aug;1(2):127-32.

41.

The T cell oncogene Tal2 is necessary for normal development of the mouse brain.

Bucher K, Sofroniew MV, Pannell R, Impey H, Smith AJ, Torres EM, Dunnett SB, Jin Y, Baer R, Rabbitts TH.

Dev Biol. 2000 Nov 15;227(2):533-44.

42.

Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene.

Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH.

EMBO J. 2000 Mar 1;19(5):843-51.

43.

The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.

Yamada Y, Pannell R, Forster A, Rabbitts TH.

Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):320-4.

44.

The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.

Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, Smith AJ, Rabbitts TH.

EMBO J. 1999 Jul 1;18(13):3564-74.

45.

Evidence for the expression of urokinase-type plasminogen activator by human venous endothelial cells in vivo.

Camoin L, Pannell R, Anfosso F, Lefevre JP, Sampol J, Gurewich V, Dignat-George F.

Thromb Haemost. 1998 Dec;80(6):961-7.

PMID:
9869168
46.

The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.

Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3890-5.

47.

An efficient system for production of recombinant urokinase-type plasminogen activator.

Tang W, Sun ZY, Pannell R, Gurewich V, Liu JN.

Protein Expr Purif. 1997 Dec;11(3):279-83.

PMID:
9425632
48.

A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.

Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V.

Biochemistry. 1996 Nov 12;35(45):14070-6.

PMID:
8916892
49.

Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes.

Jiang Y, Pannell R, Liu JN, Gurewich V.

Blood. 1996 Apr 1;87(7):2775-81.

50.

Supplemental Content

Loading ...
Support Center